Redirecting to https://apnews.com/press-release/globenewswire-mobile/beyondspring-announces-new-analyses-of-dublin-3-phase-3-study-showing-survival-benefit-of-plinabulin-docetaxel-in-post-anti-pd-l1-for-non-squamous-egfr-wt-nsclc-and-a-reduction-in-brain-metastasis-compared-to-docetaxel-at-naclc-2025-c0007f379f487bade137cb1b21fc89e2